Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 8864 entries
Sorted by: Best Match Show Resources per page
Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors.

Hepatic medicine : evidence and research

Gabrovska M, Geurs F, Ponette S, Ponette J, Bulte K, Derveaux L, Kempeneers I.
PMID: 24623997
Hepat Med. 2009 Oct 30;1:9-12. doi: 10.2147/hmer.s7574. eCollection 2009.

Few data are available on patient management in jaundice caused by liver metastases of solid tumors (nonbreast and noncolon origin). We report the first patient series consecutively treated with cisplatin weekly in patients with severe jaundice and liver failure...

Cite
Gabrovska M, Geurs F, Ponette S, et al. Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors. Hepat Med. 2009;1:9-12doi: 10.2147/hmer.s7574.
Gabrovska, M., Geurs, F., Ponette, S., Ponette, J., Bulte, K., Derveaux, L., & Kempeneers, I. (2009). Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors. Hepatic medicine : evidence and research, 19-12. https://doi.org/10.2147/hmer.s7574
Gabrovska, M, et al. "Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors." Hepatic medicine : evidence and research vol. 1 (2009): 9-12. doi: https://doi.org/10.2147/hmer.s7574
Gabrovska M, Geurs F, Ponette S, Ponette J, Bulte K, Derveaux L, Kempeneers I. Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors. Hepat Med. 2009 Oct 30;1:9-12. doi: 10.2147/hmer.s7574. eCollection 2009. PMID: 24623997; PMCID: PMC3921826.
Copy Download .nbib Format: NLM
Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin.

Journal of oncology

Sharma C, Vas AJ, Goala P, Gheewala TM, Rizvi TA, Hussain A.
PMID: 24624140
J Oncol. 2014;2014:321754. doi: 10.1155/2014/321754. Epub 2014 Jan 30.

The present study was designed to gain insight into the antiproliferative activity of ethanolic neem leaves extract (ENLE) alone or in combination with cisplatin by cell viability assay on human breast (MCF-7) and cervical (HeLa) cancer cells. Nuclear morphological...

Cite
Sharma C, Vas AJ, Goala P, et al. Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin. J Oncol. 2014;2014:321754doi: 10.1155/2014/321754.
Sharma, C., Vas, A. J., Goala, P., Gheewala, T. M., Rizvi, T. A., & Hussain, A. (2014). Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin. Journal of oncology, 2014321754. https://doi.org/10.1155/2014/321754
Sharma, Chhavi, et al. "Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin." Journal of oncology vol. 2014 (2014): 321754. doi: https://doi.org/10.1155/2014/321754
Sharma C, Vas AJ, Goala P, Gheewala TM, Rizvi TA, Hussain A. Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin. J Oncol. 2014;2014:321754. doi: 10.1155/2014/321754. Epub 2014 Jan 30. PMID: 24624140; PMCID: PMC3929266.
Copy Download .nbib Format: NLM
Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial.

Thoracic cancer

Shi Y, Hu Y, Hu X, Li X, Lin L, Han X.
PMID: 26557919
Thorac Cancer. 2015 Nov;6(6):785-91. doi: 10.1111/1759-7714.12303. Epub 2015 Aug 20.

BACKGROUND: This study evaluated the efficacy and safety of irinotecan/cisplatin (IP) and etoposide/cisplatin (EP) in extensive-stage small cell lung cancer (ES-SCLC) and the distribution of uridine diphosphate glucuronosyltransferase (UGT1A1). The relationship between UGT1A1 genotypes and patient outcomes was also...

Cite
Shi Y, Hu Y, Hu X, et al. Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thorac Cancer. 2015;6(6):785-91doi: 10.1111/1759-7714.12303.
Shi, Y., Hu, Y., Hu, X., Li, X., Lin, L., & Han, X. (2015). Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thoracic cancer, 6(6), 785-91. https://doi.org/10.1111/1759-7714.12303
Shi, Yuankai, et al. "Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial." Thoracic cancer vol. 6,6 (2015): 785-91. doi: https://doi.org/10.1111/1759-7714.12303
Shi Y, Hu Y, Hu X, Li X, Lin L, Han X. Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thorac Cancer. 2015 Nov;6(6):785-91. doi: 10.1111/1759-7714.12303. Epub 2015 Aug 20. PMID: 26557919; PMCID: PMC4632933.
Copy Download .nbib Format: NLM
Amphricrine carcinoma of the cervix-adeno neuroendocrine tumor: A case report.

Turkish journal of obstetrics and gynecology

Fadıloğlu E, Karalök A, Türkmen O, Asiltürk Ş, Öçalan R, Boran N, Ökten H, Turan T, Tulunay G.
PMID: 28913101
Turk J Obstet Gynecol. 2016 Jun;13(2):99-102. doi: 10.4274/tjod.72325. Epub 2016 Jun 15.

Adenoneuroendocrine carcinoma is a very rare form of cervical carcinoma that includes both endocrine and exocrine components. In general terms, these carcinomas progress aggressively and show early metastases due to the neuroendocrine component. The most important criteria related to...

Cite
Fadıloğlu E, Karalök A, Türkmen O, et al. Amphricrine carcinoma of the cervix-adeno neuroendocrine tumor: A case report. Turk J Obstet Gynecol. 2016;13(2):99-102doi: 10.4274/tjod.72325.
Fadıloğlu, E., Karalök, A., Türkmen, O., Asiltürk, �. �., Öçalan, R., Boran, N., Ökten, H., Turan, T., & Tulunay, G. (2016). Amphricrine carcinoma of the cervix-adeno neuroendocrine tumor: A case report. Turkish journal of obstetrics and gynecology, 13(2), 99-102. https://doi.org/10.4274/tjod.72325
Fadıloğlu, Erdem, et al. "Amphricrine carcinoma of the cervix-adeno neuroendocrine tumor: A case report." Turkish journal of obstetrics and gynecology vol. 13,2 (2016): 99-102. doi: https://doi.org/10.4274/tjod.72325
Fadıloğlu E, Karalök A, Türkmen O, Asiltürk Ş, Öçalan R, Boran N, Ökten H, Turan T, Tulunay G. Amphricrine carcinoma of the cervix-adeno neuroendocrine tumor: A case report. Turk J Obstet Gynecol. 2016 Jun;13(2):99-102. doi: 10.4274/tjod.72325. Epub 2016 Jun 15. PMID: 28913101; PMCID: PMC5558347.
Copy Download .nbib Format: NLM
LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma.

Oncotarget

Liu Z, Zhang H.
PMID: 28969069
Oncotarget. 2017 Jul 26;8(38):64273-64282. doi: 10.18632/oncotarget.19604. eCollection 2017 Sep 08.

Bladder cancer (BC) is the most lethal malignant cancer of the genitourinary system, and bladder urothelial carcinoma (BUC) is the most common type of BC. The long non-coding RNA (lncRNA) plasmacytoma variant translocation 1 (PVT1) is overexpressed in several...

Cite
Liu Z, Zhang H. LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. Oncotarget. 2017;8(38):64273-64282doi: 10.18632/oncotarget.19604.
Liu, Z., & Zhang, H. (2017). LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. Oncotarget, 8(38), 64273-64282. https://doi.org/10.18632/oncotarget.19604
Liu, Zhongyuan, and Zhang, Hui. "LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma." Oncotarget vol. 8,38 (2017): 64273-64282. doi: https://doi.org/10.18632/oncotarget.19604
Liu Z, Zhang H. LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. Oncotarget. 2017 Jul 26;8(38):64273-64282. doi: 10.18632/oncotarget.19604. eCollection 2017 Sep 08. PMID: 28969069; PMCID: PMC5610001.
Copy Download .nbib Format: NLM
TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells.

Oncology letters

Liu X, Feng M, Zheng G, Gu Y, Wang C, He Z.
PMID: 28454268
Oncol Lett. 2017 Mar;13(3):1398-1405. doi: 10.3892/ol.2016.5534. Epub 2016 Dec 27.

Platinum-based drugs, including cisplatin (DDP) and oxaliplatin (L-OHP), are among the most potent chemotherapy drugs, and are widely utilized for the treatment of human lung and ovarian cancer. However, certain patients do not respond to platinum-based agents, and even...

Cite
Liu X, Feng M, Zheng G, et al. TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells. Oncol Lett. 2016;13(3):1398-1405doi: 10.3892/ol.2016.5534.
Liu, X., Feng, M., Zheng, G., Gu, Y., Wang, C., & He, Z. (2017). TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells. Oncology letters, 13(3), 1398-1405. https://doi.org/10.3892/ol.2016.5534
Liu, Xiaorong, et al. "TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells." Oncology letters vol. 13,3 (2017): 1398-1405. doi: https://doi.org/10.3892/ol.2016.5534
Liu X, Feng M, Zheng G, Gu Y, Wang C, He Z. TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells. Oncol Lett. 2017 Mar;13(3):1398-1405. doi: 10.3892/ol.2016.5534. Epub 2016 Dec 27. PMID: 28454268; PMCID: PMC5403207.
Copy Download .nbib Format: NLM
MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1.

Oncology letters

Li J, Chen Y, Jin M, Wang J, Li S, Chen Z, Yu W.
PMID: 28454276
Oncol Lett. 2017 Mar;13(3):1451-1455. doi: 10.3892/ol.2017.5574. Epub 2017 Jan 05.

Multidrug resistance (MDR) is the primary barrier to the success of chemotherapy for lung adenocarcinoma. MicroRNA (miR)-134, which is downregulated in lung adenocarcinoma, influences cell proliferation, apoptosis and invasion of lung adenocarcinoma. However, the function of miR-134 in the...

Cite
Li J, Chen Y, Jin M, et al. MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1. Oncol Lett. 2017;13(3):1451-1455doi: 10.3892/ol.2017.5574.
Li, J., Chen, Y., Jin, M., Wang, J., Li, S., Chen, Z., & Yu, W. (2017). MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1. Oncology letters, 13(3), 1451-1455. https://doi.org/10.3892/ol.2017.5574
Li, Jipeng, et al. "MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1." Oncology letters vol. 13,3 (2017): 1451-1455. doi: https://doi.org/10.3892/ol.2017.5574
Li J, Chen Y, Jin M, Wang J, Li S, Chen Z, Yu W. MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1. Oncol Lett. 2017 Mar;13(3):1451-1455. doi: 10.3892/ol.2017.5574. Epub 2017 Jan 05. PMID: 28454276; PMCID: PMC5403496.
Copy Download .nbib Format: NLM
Human mesenchymal stem cells are resistant to cytotoxic and genotoxic effects of cisplatin in vitro.

Genetics and molecular biology

Bellagamba BC, Abreu BR, Grivicich I, Markarian CF, Chem E, Camassola M, Nardi NB, Dihl RR.
PMID: 27007906
Genet Mol Biol. 2016 Mar;39(1):129-34. doi: 10.1590/1678-4685-GMB-2015-0057.

Mesenchymal stem cells (MSCs) are known for their important properties involving multilineage differentiation potential., trophic factor secretion and localization along various organs and tissues. On the dark side, MSCs play a distinguished role in tumor microenvironments by differentiating into...

Cite
Bellagamba BC, Abreu BR, Grivicich I, et al. Human mesenchymal stem cells are resistant to cytotoxic and genotoxic effects of cisplatin in vitro. Genet Mol Biol. 2016;39(1):129-34doi: 10.1590/1678-4685-GMB-2015-0057.
Bellagamba, B. C., Abreu, B. R., Grivicich, I., Markarian, C. F., Chem, E., Camassola, M., Nardi, N. B., & Dihl, R. R. (2016). Human mesenchymal stem cells are resistant to cytotoxic and genotoxic effects of cisplatin in vitro. Genetics and molecular biology, 39(1), 129-34. https://doi.org/10.1590/1678-4685-GMB-2015-0057
Bellagamba, Bruno Corrêa, et al. "Human mesenchymal stem cells are resistant to cytotoxic and genotoxic effects of cisplatin in vitro." Genetics and molecular biology vol. 39,1 (2016): 129-34. doi: https://doi.org/10.1590/1678-4685-GMB-2015-0057
Bellagamba BC, Abreu BR, Grivicich I, Markarian CF, Chem E, Camassola M, Nardi NB, Dihl RR. Human mesenchymal stem cells are resistant to cytotoxic and genotoxic effects of cisplatin in vitro. Genet Mol Biol. 2016 Mar;39(1):129-34. doi: 10.1590/1678-4685-GMB-2015-0057. PMID: 27007906; PMCID: PMC4807379.
Copy Download .nbib Format: NLM
Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells .

Oncology letters

Harada K, Ferdous T, Harada T, Takenawa T, Ueyama Y.
PMID: 28927087
Oncol Lett. 2017 Sep;14(3):3349-3356. doi: 10.3892/ol.2017.6602. Epub 2017 Jul 18.

Gimeracil or 5-chloro-2,4-dihydroxypyridine (CDHP) enhances the antitumor effects of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU. CDHP, as part of a combination therapy, was also reported to exert a radiosensitizing effect....

Cite
Harada K, Ferdous T, Harada T, et al. Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells . Oncol Lett. 2017;14(3):3349-3356doi: 10.3892/ol.2017.6602.
Harada, K., Ferdous, T., Harada, T., Takenawa, T., & Ueyama, Y. (2017). Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells . Oncology letters, 14(3), 3349-3356. https://doi.org/10.3892/ol.2017.6602
Harada, Koji, et al. "Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells ." Oncology letters vol. 14,3 (2017): 3349-3356. doi: https://doi.org/10.3892/ol.2017.6602
Harada K, Ferdous T, Harada T, Takenawa T, Ueyama Y. Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells . Oncol Lett. 2017 Sep;14(3):3349-3356. doi: 10.3892/ol.2017.6602. Epub 2017 Jul 18. PMID: 28927087; PMCID: PMC5587992.
Copy Download .nbib Format: NLM
Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report.

Oncology letters

Kawasaki K, Hamamoto Y, Suzuki T, Hirata K, Sukawa Y, Kasuga A, Hayashi Y, Takaishi H, Kameyama K, Kanai T.
PMID: 28927133
Oncol Lett. 2017 Sep;14(3):3697-3700. doi: 10.3892/ol.2017.6601. Epub 2017 Jul 18.

Rebiopsy is considered an option for specific types of cancer, such as breast, non-small cell lung, and prostate cancer, in clinical trials and in practice. The benefit of rebiopsy comes from the selection of a new treatment strategy based...

Cite
Kawasaki K, Hamamoto Y, Suzuki T, et al. Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report. Oncol Lett. 2017;14(3):3697-3700doi: 10.3892/ol.2017.6601.
Kawasaki, K., Hamamoto, Y., Suzuki, T., Hirata, K., Sukawa, Y., Kasuga, A., Hayashi, Y., Takaishi, H., Kameyama, K., & Kanai, T. (2017). Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report. Oncology letters, 14(3), 3697-3700. https://doi.org/10.3892/ol.2017.6601
Kawasaki, Kenta, et al. "Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report." Oncology letters vol. 14,3 (2017): 3697-3700. doi: https://doi.org/10.3892/ol.2017.6601
Kawasaki K, Hamamoto Y, Suzuki T, Hirata K, Sukawa Y, Kasuga A, Hayashi Y, Takaishi H, Kameyama K, Kanai T. Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report. Oncol Lett. 2017 Sep;14(3):3697-3700. doi: 10.3892/ol.2017.6601. Epub 2017 Jul 18. PMID: 28927133; PMCID: PMC5587936.
Copy Download .nbib Format: NLM
Correction to Synergistic Anticancer Activity of Fluorescent Copper Nanoclusters and Cisplatin Delivered through a Hydrogel Nanocarrier.

ACS applied materials & interfaces

Ghosh R, Goswami U, Ghosh SS, Paul A, Chattopadhyay A.
PMID: 26376604
ACS Appl Mater Interfaces. 2015 Sep 30;7(38):21626. doi: 10.1021/acsami.5b08088. Epub 2015 Sep 17.

No abstract available.

Cite
Ghosh R, Goswami U, Ghosh SS, et al. Correction to Synergistic Anticancer Activity of Fluorescent Copper Nanoclusters and Cisplatin Delivered through a Hydrogel Nanocarrier. ACS Appl Mater Interfaces. 2015;7(38):21626doi: 10.1021/acsami.5b08088.
Ghosh, R., Goswami, U., Ghosh, S. S., Paul, A., & Chattopadhyay, A. (2015). Correction to Synergistic Anticancer Activity of Fluorescent Copper Nanoclusters and Cisplatin Delivered through a Hydrogel Nanocarrier. ACS applied materials & interfaces, 7(38), 21626. https://doi.org/10.1021/acsami.5b08088
Ghosh, Rama, et al. "Correction to Synergistic Anticancer Activity of Fluorescent Copper Nanoclusters and Cisplatin Delivered through a Hydrogel Nanocarrier." ACS applied materials & interfaces vol. 7,38 (2015): 21626. doi: https://doi.org/10.1021/acsami.5b08088
Ghosh R, Goswami U, Ghosh SS, Paul A, Chattopadhyay A. Correction to Synergistic Anticancer Activity of Fluorescent Copper Nanoclusters and Cisplatin Delivered through a Hydrogel Nanocarrier. ACS Appl Mater Interfaces. 2015 Sep 30;7(38):21626. doi: 10.1021/acsami.5b08088. Epub 2015 Sep 17. PMID: 26376604.
Copy Download .nbib Format: NLM
Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.

Cancer chemotherapy and pharmacology

Edelman MJ, Lapidus R, Feliciano J, Styblo M, Beumer JH, Liu T, Gobburu J.
PMID: 27677624
Cancer Chemother Pharmacol. 2016 Nov;78(5):969. doi: 10.1007/s00280-016-3159-7.

No abstract available.

Cite
Edelman MJ, Lapidus R, Feliciano J, et al. Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer Chemother Pharmacol. 2016;78(5):969doi: 10.1007/s00280-016-3159-7.
Edelman, M. J., Lapidus, R., Feliciano, J., Styblo, M., Beumer, J. H., Liu, T., & Gobburu, J. (2016). Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer chemotherapy and pharmacology, 78(5), 969. https://doi.org/10.1007/s00280-016-3159-7
Edelman, Martin J, et al. "Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors." Cancer chemotherapy and pharmacology vol. 78,5 (2016): 969. doi: https://doi.org/10.1007/s00280-016-3159-7
Edelman MJ, Lapidus R, Feliciano J, Styblo M, Beumer JH, Liu T, Gobburu J. Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer Chemother Pharmacol. 2016 Nov;78(5):969. doi: 10.1007/s00280-016-3159-7. PMID: 27677624.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 8864 entries